A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Center for International Blood and Marrow Transplant Research
Takeda
M.D. Anderson Cancer Center
Massachusetts General Hospital
M.D. Anderson Cancer Center
University of Alabama at Birmingham
Ossium Health, Inc.
Ossium Health, Inc.
University of Miami
City of Hope Medical Center
Children's Hospital Medical Center, Cincinnati
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Novartis
Center for International Blood and Marrow Transplant Research
NextCure, Inc.
Brown University
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Nantes University Hospital
M.D. Anderson Cancer Center
Institut Claudius Regaud
Novartis
University of Arizona
Novartis
University of Iowa
UNC Lineberger Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Incyte Corporation
Constellation Pharmaceuticals
University of Alabama at Birmingham
University of Alabama at Birmingham
Affiliated Hospital of Qinghai University
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
Bristol-Myers Squibb
Massachusetts General Hospital
BlossomHill Therapeutics
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dana-Farber Cancer Institute
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
University Hospital, Bordeaux
Vor Biopharma
University of Nebraska
Northwestern University